BlackThorn Therapeutics

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

Exo Therapeutics, Inc., located in Cambridge, MA, is pioneering a new approach in medicine by unlocking challenging drug targets through its innovative Exosites platform. This comprehensive system is designed to modulate enzyme activity with precision and potency, primarily focusing on applications in oncology and inflammation. With a commitment to charting new territory in drug development, Exo Therapeutics is actively advancing its pipeline to create breakthrough medicines. Recent presentations at prominent conferences highlight the company's progress, including data on novel exosite inhibitors that disrupt pathological pathways in disease mechanisms. Generated from the website

Akashi Therapeutics, based in Cambridge, is a global biopharmaceutical company with a focus on developing innovative therapies for individuals affected by rare disorders. The company's mission is to create life-changing treatments that address the unmet medical needs of those living with rare diseases, aiming to improve the quality of life for patients worldwide. Generated from their website's infomation